# NEOGENOMICS INC (NEO) — litigation/settled [announced]
Source: SEC API (secapi.ai) · situation sit_e664874e0b395952d914 · retrieved 2026-08-11T16:16:33.801Z

## Overview
NeoGenomics, Inc. is a testing laboratory services company that provides consulting and service agreements to healthcare providers.

On July 20, 2026, NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice, acting on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services, resolving a government investigation concerning consulting services provided by the company to certain healthcare providers. The company agreed to pay $9,813,260 to resolve the matter. The settlement is neither an admission of liability by the company nor a concession by the United States that its claims are not well founded. As of March 31, 2026, the company had accrued a reserve of $11.2 million for potential damages and liabilities associated with the matters identified during the investigation.

## Terms
- Counterparty: U.S. Department of Justice (on behalf of Office of Inspector General of the U.S. Department of Health and Human Services) · Deal value: $9.8M · Consideration: cash

## Key dates
- Announced 2026-07-20

## Timeline
- 2026-07-20 · 8-K (0001077183-26-000045): 8-K - NEOGENOMICS INC — *NeoGenomics, Inc. is a leading provider of oncology diagnostic solutions specializing in cancer genetics testing and information services, offering comprehensive oncology-focused testing menus and laboratory services throughout the US and internationally.* NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice on June 20, 2026, resolving a government investigation into consulting services the company provided to healthcare providers. The company agreed to pay $9,813,260 to resolve the matter. The settlement is neither an admission of liability by the company nor a concession by the United States that its claims are not well founded. The company had previously accrued a reserve of $11.2 million as of March 31, 2026, for potential damages and liabilities associated with the investigation.
  https://www.sec.gov/Archives/edgar/data/1077183/0001077183-26-000045.txt
- 2026-07-22 · 8-K/A (0001077183-26-000049): 8-K/A - NEOGENOMICS INC — *NeoGenomics, Inc. is a testing laboratory services company that provides consulting and service agreements to healthcare providers.* On July 20, 2026, NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice, acting on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services, resolving a government investigation concerning consulting services provided by the company to certain healthcare providers. The company agreed to pay $9,813,260 to resolve the matter. The settlement is neither an admission of liability by the company nor a concession by the United States that its claims are not well founded. As of March 31, 2026, the company had accrued a reserve of $11.2 million for potential damages and liabilities associated with the matters identified during the investigation.
  https://www.sec.gov/Archives/edgar/data/1077183/0001077183-26-000049.txt

## Citations
- 0001077183-26-000045 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000107718326000045
- 0001077183-26-000049 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000107718326000049